Atlas Trials

Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma

Clinical trial NCT02965157 · UNKNOWN

Trial details

NCT number
NCT02965157
Sponsor
Beijing Biohealthcare Biotechnology Co.,Ltd
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Lymphoma, B-Cell
Start date
2016-08-01
Primary completion
2018-01-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.